Good morning :)
Place Order
Add to Watchlist

Glenmark Life Sciences Ltd

GLS

Glenmark Life Sciences Ltd

GLS
Health CarePharmaceuticals
SmallcapWith a market cap of ₹13,283 cr, stock is ranked 457
Moderate RiskStock is 2.85x as volatile as Nifty
1,085.401.29% (+13.85)
1,085.401.29% (+13.85)

Price Chart

High
Low
Returns
1D
1W
1M
1Y
5Y
Max
SIP
Loading...
1D
1W
1M
1Y
5Y
Max
SIP
Health CarePharmaceuticals
SmallcapWith a market cap of ₹13,283 cr, stock is ranked 457
Moderate RiskStock is 2.85x as volatile as Nifty

How to use scorecard? Learn more

Health CarePharmaceuticals
SmallcapWith a market cap of ₹13,283 cr, stock is ranked 457
Moderate RiskStock is 2.85x as volatile as Nifty

Key Metrics

No LabelNo LabelPB RatioPB RatioDividend YieldDiv. Yield
31.375.702.08%
Sector PESector PESector PBSector PBSector Div YldSctr Div Yld
51.116.510.52%

Forecast & Ratings

Detailed Forecast 
83%
Analysts have suggested that investors can buy this stock

from 6 analysts

Price

Price Upside

Earnings

Earnings Growth

Revenue

Rev. Growth

See Detailed Forecast

Company Profile

Glenmark Life Sciences Ltd is a manufacturer of pharmaceutical preparation. The Company was founded in June 2011 and is located in Solapur, India.

Investor Presentation

View older 

Oct 24, 2024

PDF
View Older Presentations

Get more out of Tickertape, Go Pro!

Customise key metrics, see detailed forecasts, download stock data and more

Forecasts

Price

Revenue

Earnings

Income

Balance Sheet

Cash Flow

Income Statement

Industry refers to the sub-sector this company belongs to.

Higher than Industry Revenue Growth

A higher-than-industry revenue growth represents increased potential for the company to increase their market share

Over the last 5 years, revenue has grown at a yearly rate of 20.95%, vs industry avg of 9.03%

Increasing Market Share

Market share is the percentage of an industry's total sales going to a particular company. It gives a general idea of the size of a company v/s its competitors

Over the last 5 years, market share increased from 0.4% to 0.61%

Higher than Industry Net Income

Net income is equal to net earnings (profit) less expenses. This number is an important measure of how profitable the company is

Over the last 5 years, net income has grown at a yearly rate of 19.21%, vs industry avg of 15.27%

Loading...

Financial YearFY 2018FY 2019FY 2020FY 2021FY 2022FY 2023FY 2024TTM
Total Revenue0.25886.861,549.301,885.982,137.912,190.182,295.252,223.75
Raw Materialssubtract0.04633.56668.66948.17977.961,068.561,025.211,597.05
Power & Fuel Costsubtract0.0057.8176.7574.19100.92115.60112.46
Employee Costsubtract0.15106.28142.28149.13168.72180.18258.16
Selling & Administrative Expensessubtract0.0044.2042.0548.5048.6465.4764.12
Operating & Other expensessubtract0.08-203.15135.6174.11210.9189.11149.02
Depreciation/Amortizationsubtract0.0019.2629.3733.3937.8842.0953.4557.19
Interest & Other Itemssubtract0.000.6133.5287.5527.960.551.551.44
Taxes & Other Itemssubtract0.4232.71107.97119.37146.20161.65160.40144.56
EPS-8.0036.1029.0432.6136.3638.1138.4334.56
DPS0.000.000.000.0021.0042.0022.5022.50
Payout ratio0.000.000.000.000.581.100.590.65

Company Updates

Annual Report and Investor Presentation updates mentioned here are as reported by the company to the exchange
FY 2022

Annual report

PDF

Investor Presentation

Apr 20PDF
Feb 8PDF
FY 2023

Annual report

PDF

Investor Presentation

Apr 27PDF
Jan 27PDF
Nov 17PDF
+3 more
FY 2024

Annual report

PDF

Investor Presentation

Jul 21PDF
FY 2025

Annual Report Pending

Investor Presentation

Oct 24PDF
 

Peers & Comparison

Comparing 3 stocks from 
Health CarePharmaceuticals

Loading...

StockPE RatioPE RatioPB RatioPB RatioDiv. YieldDividend Yield
Glenmark Life Sciences Ltd28.215.702.08%
Sun Pharmaceutical Industries Ltd44.626.370.76%
Cipla Ltd30.064.620.85%
Torrent Pharmaceuticals Ltd67.9216.410.84%

Price Comparison

Compare GLS with any stock or ETF
Compare GLS with any stock or ETF
GLS
Loading...

Shareholdings

Promoter Holdings Trend

Decreased Total Promoter Holding

Increasing promoter holding is considered good and reflects management’s positive view about the future outlook

In last 6 months, promoter holding in the company has decreased by 7.85%

Low Pledged Promoter Holding

Lower pledged promoter holdings is considered better

Pledged promoter holdings is insignificant

Institutional Holdings Trend

Increased Total Retail Holding

Increasing retail holding can be considered bad as it can reflect that institutions and promoters are selling their stake which is being absorbed by retail investors.

In last 3 months, retail holding in the company has increased by 1.39%

Increased Foreign Institutional Holding

Foreign Institutional Holding is quantum of stock held by foreign large-quantities-trading entities. Increasing value indicates growing support and comfort for the stock

In last 3 months, foreign institutional holding of the company has increased by 3.04%

Tickertape Separator

Shareholding Pattern

Retail and OthersForeign InstitutionsOther Domestic InstitutionsMutual FundsTotal Promoter Holding75.00%2.82%1.34%7.85%12.98%

Dec 2023

Mar 2024

Jun 2024

Sep 2024

Shareholding History

JunSepDec '23MarJunSep3.27%4.38%4.57%5.01%4.82%7.85%

Mutual Funds Holding Trend

Increased Mutual Fund Holding

Increasing Mutual Fund holdings are generally considered good, as it reflects that fund managers are becoming more bullish about the stock

In last 3 months, mutual fund holding of the company has increased by 1.80%

Top 5 Mutual Funds holding Glenmark Life Sciences Ltd




Funds (Top 5)Market-cap heldWeight3M holding changePortfolio rank
(3M change)
Quant Flexi Cap Fund - Growth - Direct Plan

Growth
0.8661%1.53%1.53%45/46 (+1)
ICICI Prudential Pharma Healthcare and Diagnostics (P.H.D) Fund Direct Plan Growth

Growth
0.4059%1.08%-0.50%30/51 (-10)
Quant Business Cycle Fund - Growth - Direct Plan

Growth
0.3959%3.40%3.40%12/43 (+25)

Compare 3-month MF holding change on Screener

Insider Trades & Bulk Deals

Loading...

smallcases

Looks like this stock is not in any smallcase yet.

Events

Dividend Trend

No dividend trend available

Dividends

Corp. Actions

Announcements

Legal Orders

Upcoming Dividends

No upcoming dividends are available

Past Dividends

Cash Dividend

Ex DateEx DateOct 17, 2023

Interim
Interim | Div/Share: ₹22.50

Dividend/Share

22.50

Ex DateEx Date

Oct 17, 2023

Cash Dividend

Ex DateEx DateMar 24, 2023

Interim
Interim | Div/Share: ₹21.00

Dividend/Share

21.00

Ex DateEx Date

Mar 24, 2023

Cash Dividend

Ex DateEx DateSep 15, 2022

Final
Final | Div/Share: ₹10.50

Dividend/Share

10.50

Ex DateEx Date

Sep 15, 2022

Cash Dividend

Ex DateEx DateNov 22, 2021

Interim
Interim | Div/Share: ₹10.50

Dividend/Share

10.50

Ex DateEx Date

Nov 22, 2021

News & Opinions
Earnings
Glenmark Life Sciences standalone net profit declines 19.72% in the September 2024 quarter

Net profit of Glenmark Life Sciences declined 19.72% to Rs 95.32 crore in the quarter ended September 2024 as against Rs 118.74 crore during the previous quarter ended September 2023. Sales declined 14.86% to Rs 506.88 crore in the quarter ended September 2024 as against Rs 595.36 crore during the previous quarter ended September 2023. ParticularsQuarter EndedSep. 2024Sep. 2023% Var. Sales506.88595.36 -15 OPM %26.5128.07 - PBDT142.55172.06 -17 PBT127.46158.93 -20 NP95.32118.74 -20 Powered by Capital Market - Live

1 month agoCapital Market - Live
Corporate
Glenmark Life Sciences announces board meeting date

Glenmark Life Sciences will hold a meeting of the Board of Directors of the Company on 24 October 2024.Powered by Capital Market - Live

1 month agoCapital Market - Live
Corporate
Glenmark Life Sciences AGM scheduled

Glenmark Life Sciences announced that the Annual General Meeting (AGM) of the company will be held on 25 September 2024.Powered by Capital Market - Live

2 months agoCapital Market - Live

HUL, Lux Industries shares gain despite market crash

3 months agoEconomic Times

Glenmark Life Sciences Ltd leads gainers in ‘A’ group

3 months agoBusiness Standard
Spotlight
Glenmark Life Sciences Ltd leads gainers in 'A' group

Tamilnad Mercantile Bank Ltd, Marico Ltd, Rossari Biotech Ltd and Nestle India Ltd are among the other gainers in the BSE's 'A' group today, 05 August 2024.Glenmark Life Sciences Ltd soared 6.76% to Rs 939.3 at 11:46 IST. The stock was the biggest gainer in the BSE's 'A' group. On the BSE, 23295 shares were traded on the counter so far as against the average daily volumes of 23721 shares in the past one month. Tamilnad Mercantile Bank Ltd spiked 3.68% to Rs 468.7. The stock was the second biggest gainer in 'A' group. On the BSE, 1.84 lakh shares were traded on the counter so far as against the average daily volumes of 11409 shares in the past one month. Marico Ltd surged 1.94% to Rs 674.8. The stock was the third biggest gainer in 'A' group. On the BSE, 96840 shares were traded on the counter so far as against the average daily volumes of 1.4 lakh shares in the past one month. Rossari Biotech Ltd gained 1.07% to Rs 918.7. The stock was the fourth biggest gainer in 'A' group. On the BSE, 89730 shares were traded on the counter so far as against the average daily volumes of 19439 shares in the past one month. Nestle India Ltd advanced 0.68% to Rs 2511.3. The stock was the fifth biggest gainer in 'A' group. On the BSE, 16742 shares were traded on the counter so far as against the average daily volumes of 51971 shares in the past one month. Powered by Capital Market - Live

3 months agoCapital Market - Live

Stock that will see action today: July 29, 2024

4 months agoThe Hindu Businessline

Glenmark Life drops after Q1 PAT slides 18% YoY to Rs 111 cr

4 months agoBusiness Standard

Glenmark Life Sciences standalone net profit declines 17.70% in the June 2024 quarter

4 months agoBusiness Standard
Earnings
Glenmark Life Sciences standalone net profit declines 17.70% in the June 2024 quarter

Net profit of Glenmark Life Sciences declined 17.70% to Rs 111.48 crore in the quarter ended June 2024 as against Rs 135.45 crore during the previous quarter ended June 2023. Sales rose 1.76% to Rs 588.62 crore in the quarter ended June 2024 as against Rs 578.45 crore during the previous quarter ended June 2023. ParticularsQuarter EndedJun. 2024Jun. 2023% Var. Sales588.62578.45 2 OPM %27.1033.39 - PBDT164.63194.62 -15 PBT150.24182.01 -17 NP111.48135.45 -18 Powered by Capital Market - Live

4 months agoCapital Market - Live